Clinical Trial to eLiminate HCV-infection in Treatment-naïve, Renally Impaired EgyptiAn Patients on Renal Dialysis, With Chronic Hepatitis C Genotype 4

• Status: Withdrawn
• Trial end date: 2020-06-01
• Target enrollment: 0
• Participant gender: All

Summary

Primary Efficacy Objective

-To assess whether a 12-week treatment course with oral 50 mg elbasvir plus 100 mg grazoprevir given in a single daily dose to treatment-naïve patients with end-stage renal disease (ESRD) and infected with genotype 4 (GT4) chronic HCV (CHC) infection can produce a sustained viral response (SVR), i.e. HCV RNA below the lower limit of quantification [LLOQ] for 12 weeks (SVR12) after completion of the study treatment course

Secondary Objectives

• To assess the efficacy of elbasvir/grazoprevir in suppressing HCV viremia in treatment-naïve GT4 CHC patients at each scheduled visit and clinically meaningful endpoints (Week 2, 8 and 12 [End of Treatment - EOT]) and 24 (SVR12)

• To assess the safety and tolerability of a 12-week treatment course with elbasvir/grazoprevir in treatment-naïve patients with ESRD and infected with GT4 CHC.

• To assess liver fibrosis by non-invasive evaluation of liver stiffness (Fibroscan®) in the same patients before treatment and EOT and SVR12

Clinical hypotheses.

Primary Efficacy Hypothesis

• A 12-week treatment course with elbasvir/grazoprevir in treatment-naïve patients with ESRD and infected with GT4 CHC infection will result in an HCV RNA below the LLOQ in 95% of patients within 2 weeks of treatment, and at least 95% will have an SVR12.

Secondary hypotheses

• A 12-week treatment course with elbasvir/grazoprevir in ESRD GT4 treatment-naïve patients will result in undetectable viremia in 95% patients at Week 2, 4, 8 and 12 (EOT) and 24 (SVR12)

• Treatment will be safe and well-tolerated in these patients, as determined by the type and number of adverse events identified through laboratory testing, vital signs and physical examinations.

• In these patients with liver fibrosis before treatment, the liver fibrosis as assessed by non-invasive evaluation of liver stiffness (Fibroscan®) will improve by EOT and SVR12

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Maryland, Baltimore
• Collaborators: Cairo University; Merck Sharp & Dohme Corp.
• Treatments: Elbasvir-grazoprevir drug combination; Grazoprevir

Criteria

Inclusion Criteria:

1. Signed and dated informed consent obtained before undergoing any trial-related procedures

2. Male and female patients; age between 21 and 70 years inclusive

3. Chronic hepatitis C infection with genotype 4 confirmed by genotypic testing at screening or within 6 months of screening period

4. Treatment naïve - absence of prior failed treatment for HCV with Interferon plus ribavirin therapy or directly acting antivirals (treatment experienced)

5. Detectable HCV viral load (quantitative)

6. Liver cirrhosis subjects may be included but will be limited to those with compensated liver disease

7. Chronic kidney disease with end-stage liver disease (defined as glomerular filtration rate [eGFR] <=15 mL/min/1.73m2) on hemodialysis for at least 3 months, including individuals awaiting kidney transplant and those with failed kidney transplants but no longer on immunosuppressant therapy)

8. Screening laboratory values within the defined protocol thresholds

9. Women of child-bearing potential, must agree to abstinence or use of effective contraceptive methods (e.g. oral or injectable contraceptives, intra-uterine device (IUD), transdermal contraceptive patch) at least 2 weeks prior Day 1 through 14 days after the last dose of the study drug.

10. Ability to communicate, participate, and comply with the requirements of the entire study

Exclusion Criteria:

1. Patients didn't sign informed consent or under age of legal consent

2. Pregnant or breastfeeding woman

3. Has HCV genotypes other than G4

4. On peritoneal dialysis for management of kidney disease

5. Co-Infection with HIV and/or HBV (with positive HBsAg)

6. Evidence of hepatocellular carcinoma (HCC)

7. Evidence of hepatic decompensation as evidenced by presence or history of ascites, esophaegal or gastric bleeding, hepatic encelopathy or other signs of or symptoms of advanced liver disease, or cirrhotic subjects with Child-Pugh B or C, or who have a Purgh-Turcotte (CPT) score >6

8. Active or suspected non-hepatic malignancy or history of any malignancy except for cured basal cell or squamous cell skin cancer or in situ cervical cancer

9. Organ transplant (including hematopoietic stem cell transplant) other than kidney, cornea, and hair

10. Conditions requiring, or likely to require, chronic systemic administration of corticosteroids during the course of the trial

11. Uncontrolled or poorly controlled hypertension

12. Pregnant, breast-feeding, expecting to conceive or donate eggs, or donate sperm from Day 1 through 14 days after the last study dose.

13. Significant cardiovascular disorder (e.g. myocardial infarction or unstable angina) or interventional cardiovascular procedure within 3 months prior to signing informed consent

14. Recent (within 3 months prior to signing informed consent) episode or recurrence of stroke, transient ischemic attack (TIA) or neurological disorder, including but not limited to seizures

15. ALT or AST > 10-fold the upper limit of normal

16. Evidence of liver disease due to causes other than chronic HCV infection

17. Evidence of poorly controlled diabetes (defined as HbA1c > 8%)

18. History of alcohol or drug abuse within the last 12 months

19. Serum albumin level < 3.0 g/dL

20. INR > 1.3 N

21. Total Bilirubin levels > 2.0 mg/dL unless explained by Gilbert's disease

22. Platelets Count <75,000/µL

23. White blood cell count < 1500 µL (mm3)

24. Clinically significant TSH and T4 level poorly controlled thyroid function

25. Patients with any abnormality on physical examination, vital signs (sitting systolic blood pressure greater than 150 mmHg, sitting diastolic blood pressure greater than 90 mmHg and pulse greater than 90 bpm) and ECG, unless these abnormalities are judged to be not clinically significant by the Investigator

26. Body Mass Index < 18.5 or > 35 kg/m2

27. Use of other investigational drugs/treatments within the previous 3 months

28. Known hypersensitivity to any of the test materials or related compounds.

29. Active autoimmune disease.

30. History of moderate, severe or uncontrolled psychiatric disease, especially severe depression and prior suicidal attempt.

31. Unable to comply with research study visits.

32. Poor venous access not allowing screening laboratory collection.

33. Any other condition that, in the opinion of the Investigator, may be a contraindication to study participation or jeopardize the study conduct according to the protocol.